Zoetis (ZTS) Total Non-Current Liabilities (2012 - 2026)

Zoetis' (ZTS) quarterly Total Non-Current Liabilities came in at $11.6 billion in Q1 2026, up 26.99% year-on-year from $9.2 billion in Q1 2025, and down 1.56% on a QoQ basis from $11.8 billion in Q4 2025.

Zoetis (ZTS) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has 15 years of Total Non-Current Liabilities data on file, last reported at $11.6 billion in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 26.99% year-over-year to $11.6 billion in Q1 2026; TTM through Mar 2026 was $11.6 billion, a 26.99% increase from a year earlier, with the FY2025 full-year figure at $11.8 billion, up 28.6% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $11.6 billion, down from $11.8 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ZTS reached as high as $11.8 billion in Q4 2025 and fell as low as $8.8 billion in Q3 2022.
  • Historically, Total Non-Current Liabilities has averaged $9.4 billion across 5 years, with a median of $9.1 billion in 2023.
  • Across the five-year window, Total Non-Current Liabilities fell 11.75% in 2023 and gained 28.6% in 2025, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $10.3 billion in 2022, then fell by 11.75% to $9.1 billion in 2023, then advanced by 1.51% to $9.2 billion in 2024, then climbed by 28.6% to $11.8 billion in 2025, then dropped by 1.56% to $11.6 billion in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $11.6 billion in Q1 2026, $11.8 billion in Q4 2025, and $9.5 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 604.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 11.64 Bn
Dec 31, 2025 11.83 Bn
Sep 30, 2025 9.50 Bn
Jun 30, 2025 9.23 Bn
Mar 31, 2025 9.17 Bn
Dec 31, 2024 9.20 Bn
Sep 30, 2024 8.85 Bn
Jun 30, 2024 8.98 Bn
Mar 31, 2024 9.07 Bn
Dec 31, 2023 9.06 Bn
Sep 30, 2023 8.77 Bn
Jun 30, 2023 8.91 Bn
Mar 31, 2023 9.05 Bn
Dec 31, 2022 10.26 Bn
Sep 30, 2022 8.77 Bn
Jun 30, 2022 8.96 Bn
Mar 31, 2022 8.96 Bn
Dec 31, 2021 9.12 Bn
Sep 30, 2021 8.77 Bn
Jun 30, 2021 9.46 Bn